A Multicenter, Open-label, Phase 2 Basket Study of MK-7684A, a Coformation of Vibostolimab (MK-7684) with Pembrolizumab (MK-3475), With or Without Other Anticancer Therapies in Participants with Selected Solid Tumors
Latest Information Update: 17 Jul 2024
At a glance
- Drugs Cisplatin (Primary) ; Fluorouracil (Primary) ; Lenvatinib (Primary) ; Paclitaxel (Primary) ; Pembrolizumab (Primary) ; Vibostolimab+pembrolizumab (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Biliary cancer; Carcinoma; Cervical cancer; Cholangiocarcinoma; Endometrial cancer; Gallbladder cancer; Gastric cancer; Head and neck cancer; Liver cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer
- Focus Therapeutic Use
- Acronyms KEYVIBE-005
- Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 04 Jun 2024 Results(n=40, data cutoff (Oct 24, 2023)) discussing data from cohort B1of this trial , presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 15 May 2024 According to a Merck & Co media release, data from this trial will be presented will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from May 31-June.
- 23 Dec 2022 Planned End Date changed from 19 Feb 2025 to 22 Feb 2027.